CLINICAL TRIALS PROFILE FOR INTRALIPID 10%
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Intralipid 10%
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00005889 ↗ | Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion | Unknown status | Baylor College of Medicine | N/A | 1999-10-01 | RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels. |
| NCT00005889 ↗ | Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion | Unknown status | National Center for Research Resources (NCRR) | N/A | 1999-10-01 | RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels. |
| NCT00048646 ↗ | Progesterone Treatment of Blunt Traumatic Brain Injury | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/Phase 2 | 2002-05-01 | The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury. |
| NCT00048646 ↗ | Progesterone Treatment of Blunt Traumatic Brain Injury | Completed | David Wright | Phase 1/Phase 2 | 2002-05-01 | The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury. |
| NCT00074477 ↗ | Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | 2003-10-01 | The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings. |
| NCT00088647 ↗ | Study Evaluating MST-997 in Advanced Malignant Solid Tumors | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 1969-12-31 | The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Intralipid 10%
Condition Name
Clinical Trial Locations for Intralipid 10%
Trials by Country
Clinical Trial Progress for Intralipid 10%
Clinical Trial Phase
Clinical Trial Sponsors for Intralipid 10%
Sponsor Name
